Views & Analysis Do research with us, not on us More needs to be done to ensure patient centricity is at the heart of all clinical trials.
Views & Analysis Patient-centricity and pharma: where are we now? How should the industry define patient-centricity, and how should progress be measured?
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
Debates & Insight Sponsored Patient centricity: Identifying how Boehringer Ingelheim UK ... Boehringer Ingelheim UK provides an update on its patient centricity initiative ahead of a new white paper later this year.
Views & Analysis Clinical trial lay summaries: a clearer picture emerges EC wants pharma to make clinical trial results more patient-friendly.
News BioMarin ends year with $4.8bn play for Amicus BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
